Metacrine, Inc. - ESG Rating & Company Profile powered by AI
If you are employed by Metacrine, Inc. and you wish to use your ESG aseessment, please get in touch. Browse to the end of the webpage for potential risks for Metacrine, Inc. based on industry, geography and size. This report of Metacrine, Inc. is assembled by All Street Sevva using advanced NLP.
Metacrine, Inc. in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 0.9; made up of an environmental score of 2.7, social score of 0.0 and governance score of 0.0.
0.9
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1810 | XBiotech Inc | 1.1 | Low |
| 1826 | Mitsubishi Tanabe Pharma Corp | 1.0 | Low |
| 1827 | Metacrine, Inc. | 0.9 | Low |
| 1827 | CannTrust Holdings Inc | 0.9 | Low |
| 1827 | Cannabis Poland SA | 0.9 | Low |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Metacrine, Inc. have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Metacrine, Inc. disclose current and historical energy intensity?
Sign up for free to unlockDoes Metacrine, Inc. report the average age of the workforce?
Sign up for free to unlockDoes Metacrine, Inc. reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Metacrine, Inc. disclose its ethnicity pay gap?
Sign up for free to unlockDoes Metacrine, Inc. disclose cybersecurity risks?
Sign up for free to unlockDoes Metacrine, Inc. offer flexible work?
Sign up for free to unlockDoes Metacrine, Inc. have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Metacrine, Inc. disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Metacrine, Inc. conduct supply chain audits?
Sign up for free to unlockDoes Metacrine, Inc. disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Metacrine, Inc. conduct 360 degree staff reviews?
Sign up for free to unlockDoes Metacrine, Inc. disclose the individual responsible for D&I?
Sign up for free to unlockDoes Metacrine, Inc. disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Metacrine, Inc. disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Metacrine, Inc. disclose water use targets?
Sign up for free to unlockDoes Metacrine, Inc. have careers partnerships with academic institutions?
Sign up for free to unlockDid Metacrine, Inc. have a product recall in the last two years?
Sign up for free to unlockDoes Metacrine, Inc. disclose incidents of discrimination?
Sign up for free to unlockDoes Metacrine, Inc. allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Metacrine, Inc. issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Metacrine, Inc. disclose parental leave metrics?
Sign up for free to unlockDoes Metacrine, Inc. disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Metacrine, Inc. disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Metacrine, Inc. disclose the pay ratio of women to men?
Sign up for free to unlockDoes Metacrine, Inc. support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Metacrine, Inc. disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Metacrine, Inc. reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Metacrine, Inc. involved in embryonic stem cell research?
Sign up for free to unlockDoes Metacrine, Inc. disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Metacrine, Inc. disclose its waste policy?
Sign up for free to unlockDoes Metacrine, Inc. report according to TCFD requirements?
Sign up for free to unlockDoes Metacrine, Inc. disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Metacrine, Inc. disclose energy use targets?
Sign up for free to unlockDoes Metacrine, Inc. disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Metacrine, Inc. have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Metacrine, Inc.
These potential risks are based on the size, segment and geographies of the company.
Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with liver and gastrointestinal diseases. It is developing MET409 that has completed Phase 1b proof-of-concept clinical trial for the treatment of patients with non-alcoholic steatohepatitis (NASH); and is in Phase 2a clinical trial in combination with empagliflozin for the treatment of patients with type 2 diabetes mellitus and NASH. The company also develops MET642, which is in Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis patients. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.